Q1 Earnings Estimate for TVTX Issued By Wedbush

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Equities research analysts at Wedbush issued their Q1 2026 earnings per share estimates for shares of Travere Therapeutics in a report issued on Wednesday, April 16th. Wedbush analyst L. Chico forecasts that the company will post earnings of ($0.02) per share for the quarter. The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics' Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.46 EPS, Q4 2026 earnings at $0.55 EPS, FY2026 earnings at $1.21 EPS and FY2029 earnings at $5.78 EPS.

Several other brokerages have also recently commented on TVTX. Canaccord Genuity Group increased their target price on shares of Travere Therapeutics from $45.00 to $47.00 and gave the stock a "buy" rating in a report on Thursday, April 10th. HC Wainwright raised their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a report on Wednesday, January 15th. Bank of America upped their target price on Travere Therapeutics from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. JPMorgan Chase & Co. increased their price target on Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, Evercore ISI boosted their price target on Travere Therapeutics from $33.00 to $45.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, Travere Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $32.08.

Travere Therapeutics Stock Up 5.9 %

NASDAQ:TVTX traded up $0.93 during trading hours on Friday, reaching $16.81. 837,710 shares of the stock were exchanged, compared to its average volume of 1,519,435. The stock has a market cap of $1.49 billion, a PE ratio of -4.10 and a beta of 0.84. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $25.29. The firm has a 50 day moving average of $18.57 and a 200 day moving average of $18.60. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.15). The company had revenue of $74.79 million during the quarter, compared to the consensus estimate of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%.

Hedge Funds Weigh In On Travere Therapeutics

A number of large investors have recently made changes to their positions in the company. Driehaus Capital Management LLC increased its position in Travere Therapeutics by 608.1% during the 4th quarter. Driehaus Capital Management LLC now owns 2,217,975 shares of the company's stock worth $38,637,000 after buying an additional 1,904,733 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Travere Therapeutics in the fourth quarter valued at about $21,075,000. RA Capital Management L.P. bought a new position in Travere Therapeutics during the fourth quarter worth about $20,033,000. Jennison Associates LLC bought a new position in Travere Therapeutics during the fourth quarter worth about $14,222,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in Travere Therapeutics by 36.7% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 2,174,213 shares of the company's stock worth $37,875,000 after purchasing an additional 583,836 shares in the last quarter.

Insiders Place Their Bets

In other Travere Therapeutics news, CAO Sandra Calvin sold 54,244 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $1,356,100.00. Following the transaction, the chief accounting officer now directly owns 54,410 shares of the company's stock, valued at $1,360,250. This represents a 49.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP William E. Rote sold 8,951 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $19.78, for a total transaction of $177,050.78. Following the sale, the senior vice president now owns 95,719 shares of the company's stock, valued at $1,893,321.82. This trade represents a 8.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 172,330 shares of company stock valued at $3,827,377 over the last ninety days. 3.75% of the stock is currently owned by company insiders.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.